Angiocidin

Drug Profile

Angiocidin

Latest Information Update: 20 Jul 2016

Price : $50

At a glance

  • Originator Drexler University Health Sciences
  • Developer Diffregen; Drexler University Health Sciences; InKine Pharmaceutical
  • Class Antineoplastics
  • Mechanism of Action Angiogenesis inhibitors; Thrombospondin antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia
  • Discontinued Solid tumours

Most Recent Events

  • 04 Oct 2005 InKine Pharmaceutical has been acquired by Salix Pharmaceuticals
  • 26 Apr 2004 Discontinued - Preclinical for Solid tumours in USA (unspecified route)
  • 07 Apr 2003 No development reported - Preclinical for Solid tumours in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top